Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1489101 | 0.80 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL1489102 | 0.78 | ALDH1A1 (0.38) | ALDH1A1TSHR | |
| SCHEMBL3453844 | 0.77 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL612528 | 0.76 | ALDH1A1 (0.37) | ALDH1A1TSHRMAPT | |
| SCHEMBL3469849 | 0.76 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL1257020 | 0.76 | TSHR (0.40) | ALDH1A1TSHR | |
| SCHEMBL1349903 | 0.76 | GRIN2D (0.33) | — | |
| Hydrochloric Acid SCHEMBL28514951 | 0.74 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| Acetic Acid SCHEMBL28451523 | 0.73 | ALDH1A1 (0.34) | ALDH1A1TSHR | |
| SCHEMBL986380 | 0.73 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | claimed |
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | US | claimed |
| WO-2012148550-A1 | PRODRUGS OF THERAPEUTIC COMPOUNDS | MYREXIS, INC. (US) | 2012-11-01 | — | — | WO | claimed |
| EP-2473475-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | AllTranz Inc. (US) | 2012-07-11 | — | — | EP | claimed |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | US | claimed |
| WO-2011026144-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | ALLTRANZ INC. (US) | 2011-03-03 | — | — | WO | claimed |
| EP-2176208-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-04-21 | — | — | EP | claimed |
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | US | claimed |
| WO-2009018389-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-11873272-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | Niche Biopharmaceuticals LLC (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3064199-B1 | ABUSE-DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | BUZZZ PHARMACEUTICALS LTD (IE) | 2023-12-20 | — | — | EP | disclosed |
| EP-4214191-A1 | ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES | Niche Biopharmaceuticals LLC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230174473-A1 | ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES | Niche Biopharmaceuticals LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-11572342-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | Niche Biopharmaceuticals LLC (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2009120889-A2 | ABUSE DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | ALLTRANZ INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090246265-A1 | ABUSE DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | ALLTRANZ INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009018389-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-5057610-A | Oxidation, heat and radiation resistance | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| US-4758614-A | Compositions stabilized with substituted amino carbamates | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036523-A1 | PRODRUGS OF CANNABIDIOL, COMPOSITIONS COMPRISING PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | ALDH1A1 1490/4885TSHR 3837/4885FGFR4 2081/4885 |
| US-20110052694-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | ALDH1A1 3684/4885TSHR 2425/4885FGFR4 1353/4885 |
| US-20090246265-A1 | ABUSE DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 373/4885TSHR 611/4885FGFR4 3161/4885 |
| US-11572342-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | MAVS, SARS1, MGLL | ALDH1A1 3686/4885TSHR 4785/4885FGFR4 3731/4885 |
| US-11873272-B2 | Antimicrobial and antiviral sulfur containing glycerol monoester derivatives | MAVS, SARS1, MGLL | ALDH1A1 3686/4885TSHR 4785/4885FGFR4 3731/4885 |
| US-20230174473-A1 | ANTIMICROBIAL AND ANTIVIRAL SULFUR CONTAINING GLYCEROL MONOESTER DERIVATIVES | MAVS, SARS1, MGLL | ALDH1A1 3686/4885TSHR 4785/4885FGFR4 3731/4885 |
| US-20150197484-A1 | USE OF CANNABIDIOL PRODRUGS IN TOPICAL AND TRANSDERMAL ADMINISTRATION WITH MICRONEEDLES | PNLIP, CNR2, CNR1 | ALDH1A1 3684/4885TSHR 2425/4885FGFR4 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.